Recognized as a leading player in cross-border pharmaceutical direct mail, especially generic drug delivery, Qizhouke owes its core advantages to complete compliance qualifications, solid supply chain barriers, efficient logistics speed, extensive grassroots coverage and a large user base. Its business model has become an industry benchmark, leaving it virtually unrivaled in the segmented track of direct mail for anti-tumor and rare disease generic drugs.

I. Compliance Qualifications: Rare Industry Threshold for Legal Direct Mail

Possessing complete dual-country qualifications in Laos and India, both Laos Qizhouke International Pharmaceutical Group and India Gaoshi International hold official pharmaceutical business licenses, overseas pharmacy credentials, pharmaceutical warehouse filings and cross-border e-commerce pilot qualifications. As one of the few cross-border pharmaceutical platforms qualified for retail direct mail of anti-cancer targeted drugs and rare disease medications, it has passed official cross-border pharmaceutical pilot reviews.

Full-process traceability is realized via one item one code and synchronized item-code tracking. Complete customs clearance documents are provided for every order, which fundamentally distinguishes its business from unregulated private purchasing channels.

It serves as a compliance benchmark under strict supervision. Being a key supervision target of pharmaceutical authorities, customs and foreign exchange administrations, it has maintained zero major violations over the years, building formidable barriers in credibility and standardized operation.

II. Supply Chain: Direct Sourcing & Exclusive Agency, Top-tier Industrial Strength

It maintains direct cooperation with world-class generic pharmaceutical manufacturers including India Natco, Cipla, Laos Alliance Pharma, Lucius and Big Bear, eliminating all intermediate distributors. It holds exclusive and core general agency rights for many globally popular anti-cancer medicines, covering the full product line of Laos Alliance Pharma.

Backed by India Gaoshi Group and Laos Qizhouke Pharmaceutical Group, it gains priority supply access to first generic drugs and achieves the fastest market synchronization of new medicines in China.

It boasts the most comprehensive product specifications, covering hundreds of essential medicines for tumors, liver diseases, targeted therapy, immunotherapy and rare diseases.